This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY or LMAT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ESLOY vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 26.37% and 8.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Q4 Earnings Lag Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -9.09% and -2.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is ProShares Russell 2000 Dividend Growers ETF (SMDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMDV
Is ProShares Russell 2000 Dividend Growers ETF (SMDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMDV
LeMaitre Vascular (LMAT) Beats Q2 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 17.65% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LeMaitre Vascular (LMAT) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
LeMaitre Vascular (LMAT) Matches Q1 Earnings Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and 0.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.